Israeli Prime Minister Benjamin Netanyahu has disclosed that he recently underwent successful treatment for a malignant prostate tumour, revealing that the diagnosis was made months earlier but intentionally kept private.
Netanyahu, 76, made the announcement on Friday during the release of details from his annual medical examination, explaining that he delayed public disclosure for about two months. According to him, the decision was taken to prevent the information from being exploited politically by Iran amid ongoing tensions.
The revelation comes after the prime minister had earlier undergone surgery for an enlarged prostate in December 2024. During routine follow-up examinations after that procedure, doctors reportedly detected a small malignant tumour measuring less than one centimetre.
Medical reports from his team described the condition as an early-stage finding, noting that the tumour was localised and had not spread to other parts of the body. The documentation characterised it as “an early detection of a very small lesion, with no metastases,” indicating a favourable prognosis.
Sources familiar with the matter said the diagnosis had been made several months ago, prompting a course of targeted radiation therapy. Netanyahu is understood to have completed the treatment recently, with doctors monitoring his progress throughout the process.
Reflecting on the outcome, the prime minister expressed relief and gratitude, stating that the tumour had been successfully eliminated.
“The spot disappeared completely,” he said, adding in a social media post, “Thank God, I am healthy.”
Netanyahu described the condition as a “minor medical issue with my prostate that was completely treated,” emphasising that the early detection played a crucial role in achieving a positive outcome.
The announcement has drawn attention given Netanyahu’s central role in Israeli politics and ongoing regional developments. Health disclosures involving national leaders often carry political and public interest implications, particularly in times of heightened geopolitical tension.
Observers note that the decision to delay the announcement reflects the sensitive intersection between health, leadership, and national security considerations. Netanyahu’s reference to concerns about potential propaganda underscores the broader strategic environment in which such decisions are made.
Medical experts generally stress that early detection of prostate cancer significantly improves treatment outcomes, with many cases successfully managed when identified at an initial stage. The description provided by Netanyahu’s medical team aligns with this understanding, suggesting that the condition was addressed before it could advance.
While the prime minister has now publicly confirmed his recovery, the episode highlights the importance of regular health screenings, particularly for older individuals. Routine examinations are often key to identifying conditions that may not initially present noticeable symptoms.
As of now, Netanyahu has resumed his official duties, with no indication that the medical issue has affected his capacity to lead. His statement appears intended to reassure both domestic and international audiences about his health status.
The disclosure adds a personal dimension to the political landscape, even as attention remains focused on broader regional and diplomatic developments involving Israel and its neighbours.
